Artificially controlled degradable nanoparticles for contrast switch MRI and programmed cancer therapy
Authors Yun T, Liu Y, Yi S, Jia Q, Liu Y, Zhou J
Received 1 August 2018
Accepted for publication 23 September 2018
Published 24 October 2018 Volume 2018:13 Pages 6647—6659
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Linlin Sun
Tianyang Yun,1 Yuxin Liu,2 Shaoqiong Yi,1 Qi Jia,2 Yang Liu,1 Jing Zhou2
1Department of Thoracic Surgery, Chinese People’s Liberation Army General Hospital, Beijing 100853, People’s Republic of China; 2Department of Chemistry, Capital Normal University, Beijing 100048, People’s Republic of China
Background: Utilizing the permeability enhancement and irreversible biomolecule denaturation caused by hyperthermia, photothermal-chemo synergistic therapy has shown great potential in clinical cancer treatment.
Purpose: The objective of this study was to provide a novel controlled drug release method to improve the efficiency of photothermal-chemo synergistic therapy.
Patients and methods: HCT116 tumor-bearing mice were selected as modal for the study of cancer theranostics efficiency. The T2 to T1 magnetic resonance imaging contrast switch was studied in vivo. Analyses of the tumor growth of mice were carried out to evaluate the tumor therapy efficiency.
Results: we developed novel artificially controlled degradable Co3O4 nanoparticles and explored their potential in drug delivery/release. In the presence of ascorbic acid (AA), the designed nanomaterials can be degraded via a redox process and hence release the loaded drugs. Importantly, the AA, in the lack of l-gulonolactone oxidase, cannot be synthesized in the body of typical mammal including human, which suggested that the degradation process can be controlled artificially. Moreover, the obtained nanoparticles have outstanding photothermal conversion efficiency and their degradation can also result in an magnetic resonance imaging contrast enhancement switch from T2 to T1, which benefits the cancer theranostics.
Conclusion: Our results illustrated that the artificially controlled degradable nanoparticles can serve as an alternative candidate for controllable drug release as well as a platform for highly efficient photothermal-chemo synergistic cancer theranostics.
Keywords: photothermal, degradable, controllable drug release, synergistic therapy, MRI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]